CytoSorbents Corporation (CTSO)

[alexander77]

CytoSorbents Corporation to Exhibit at the Force Health Protection Conference and ATACCC

CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company using blood purification to treat life-threatening illnesses, announced that it is exhibiting at two leading military healthcare conferences in August. The first is the 13th Annual Force Health Protection Conference (FHP) at the Phoenix Convention Center in Phoenix, Arizona, where CytoSorbents will exhibit in Booth #507 from August 10-11, 2010 (http://phc.amedd.army.mil/fhpc/). The FHP conference is expected to gather more than 2,000 healthcare medical providers, policymakers and vendors from around the world, focused on the latest research, services and products for disease prevention and treatment, safety and homeland security for both military and public health purposes.

The second is the Advanced Technology Applications for Combat Casualty Care (ATACCC) Conference to be held at the Tradewinds Beach Resort, in St. Pete Beach, Florida. CytoSorbents will be exhibiting from August 16-19, 2010 in Booth #19. ATACCC is the Department of Defenses' premier scientific meeting that addresses critical advances in trauma medicine and the unique medical needs of the warfighter (https://www.ataccc.org/). At both venues, the Company will be showcasing its blood purification technology with a hands-on demonstration of how the device works, how it is easily administered, and how it could be applied in a number of clinical situations facing critically wounded military personnel.


"Dr. Phillip Chan, Chief Executive Officer and President, commented, "Members of our military forces put their lives on the line every day, not only in Iraq and Afghanistan, but all over the world. The injuries they sustain in protecting our freedom include penetrating wound injuries, infection and sepsis, and blast, trauma, crush and burn injuries that are extremely complex and severe. Standard of care therapy remains predominantly supportive, and does not address the cytokine storm and subsequent severe inflammation that can lead to multi-organ failure and death in these patients."

Dr. Chan continued, "We believe that our flagship product CytoSorb™, a powerful cytokine removal technology currently in human clinical trials, is the key to changing the current treatment paradigm of 'supportive care and watchful waiting' to one of 'active treatment,' potentially saving more lives. In addition, blood purification using CytoSorb or other resins under development, may solve many other vexing problems facing the military and the DOD, such as how to treat soldiers or civilians exposed to chemical or biologic warfare. Exhibiting at these major conferences continues our efforts to build funding support for our technologies within the military and the DOD and to expand the number of clinical applications for our products."

http://app.quotemedia.com/quotetools/newsStoryPopup.go?storyId=32644040&topic=CTSO&symbology=null&cp=off&webmasterId=94743


G-R-E-A-T


+ 11 August LSI presentation!!!